BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
39 hedge funds and large institutions have $15.3M invested in BRAINSTORM CELL THERAPUTC in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 7 closing their positions.
140% more call options, than puts
Call options by funds: $1.67M | Put options by funds: $698K
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
0.05% less ownership
Funds ownership: 0.82% → 0.76% (-0.05%)
9% less funds holding
Funds holding: 43 → 39 (-4)
14% less capital invested
Capital invested by funds: $17.7M → $15.3M (-$2.44M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$310K |
| 2 |
JP Morgan Chase
New York
|
+$174K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$161K |
| 4 |
AHB
Abner Herrman & Brock
Jersey City,
New Jersey
|
+$105K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$78.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.05M |
| 2 |
WCG
Weaver Consulting Group
Huntington Beach,
California
|
-$83.5K |
| 3 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$40K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$31K |
| 5 |
Millennium Management
New York
|
-$29.2K |
BCLI Hedge Fund Activity: Q1 2022 in Review
39 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2022, worth a combined $15.3M — down 14% from $17.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BCLI and 4 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 10 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $310K. The largest seller was Sabby Management, exiting entirely with an estimated $2.05M sold.
- 39 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2022, down from 43 in Q4 2021.
- Funds reported $15.3M of BRAINSTORM CELL THERAPUTC stock for Q1 2022, down 14% quarter-over-quarter.
- 4 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2022 and 7 closed out, a net change of -3 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2022 was Susquehanna International Group, an estimated $310K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q1 2022 was Sabby Management, an estimated $2.05M sold.
Based on aggregated 13F filings for Q1 2022.